Status:
ACTIVE_NOT_RECRUITING
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
Lead Sponsor:
Institut Claudius Regaud
Collaborating Sponsors:
Fondation ARC
Conditions:
Leiomyosarcoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time. ...
Eligibility Criteria
Inclusion
- Patient with leiomyosarcoma.
- Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères)
- Localized or metastatic disease
- Newly diagnosed patient who has not yet initiated specific treatment for sarcoma
- Age ≥ 18 years
- Patient affiliated to a Social Security system in France.
- Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures
Exclusion
- Diagnosis of any other histological subtype of soft tissue sarcoma
- Associated pathology(ies) that may interfere with the study procedure
- Pregnant or breastfeeding woman
- Any psychological, family, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol.
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Key Trial Info
Start Date :
January 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05427461
Start Date
January 13 2023
End Date
July 1 2026
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France, 31059